SEO URLwww.firestrike.ai/deals/corstasis-esperion-acquisition-2026-1
acquisitionAnnounced · Mar 3, 2026CardiovascularSource · CredibleArticle · Factual
Esperion acquires Corstasis
David Najork · Founding Software Engineer
Published · Updated · 1 min read
Deal value
—
Target
Corstasis
Acquirer
Esperion
Merger
Status
Announced
Esperion agreed to acquire Corstasis. Reported deal value: Undisclosed. Status: Announced. Sector: Cardiovascular. Target headquarters context: Location not specified.
This page summarizes publicly available information about the transaction as of 2026-03-03. Figures and status may change as filings and press coverage update.
Esperion Therapeutics to Acquire Corstasis for $ 75 Million Upfront , Plus Up to $ 180 Million Milestones Less than 1 min read ESPR Esperion Therapeutics entered into an Agreement and Plan of Merger to acquire Corstasis for $ 75 million in upfront cash
Deal timeline
Announced
Mar 3, 2026 · tradingview.com
Additional milestones (proxy, vote, close) appear as filings and press updates are indexed.
Sector context
This transaction is classified in Cardiovascular. Figures and status may change as sources update.
Sources: tradingview.com · Primary article · FireStrike proprietary index